<DOC>
	<DOCNO>NCT00002122</DOCNO>
	<brief_summary>PRIMARY : To determine efficacy azithromycin rifabutin alone combination prevention disseminate Mycobacterium avium Complex ( MAC ) infection HIV-infected patient . To determine efficacy daily versus weekly fluconazole prevention deep fungal infection patient population . SECONDARY : To determine incidence bacterial ( include mycobacterial ) infection , cryptosporidiosis , toxoplasmosis azithromycin versus non-azithromycin containing regimen . To determine incidence oropharyngeal vaginal candidiasis patient treat daily versus weekly fluconazole . To compare survival outcome primary endpoint treatment arm .</brief_summary>
	<brief_title>A Randomized Study Daily Intermittent Prophylactic Regimens Prevention Disseminated Mycobacterium Avium Complex ( MAC ) Fungal Infections HIV-Infected Patients</brief_title>
	<detailed_description>Patients randomize receive azithromycin alone , rifabutin alone , two drug combination MAC prophylaxis . Patients treatment group receive one two dos concomitant fluconazole deep fungal prophylaxis , unless specifically exclude fluconazole randomization . Patients follow 1 2 year .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Preventive therapy isoniazid M. tuberculosis . Maintenance therapy CMV retinitis . Patients must : HIV infection history AIDSdefining condition CDC criterion . One document CD4 count &lt; 100 cells/mm3 within 12 month prior study entry . NO active MAC disease , MAC bacteremia , active mycobacterial infection ( tuberculous nontuberculous ) . NO acute opportunistic infection . Life expectancy 6 month . Consent parent guardian less legal age consent . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : ALL PATIENTS Unexplained fever , elevation alkaline phosphatase , pancytopenia , abnormal liver function test , odynophagia diagnosis MAC fungal infection exclude . Serious hypersensitivity reaction macrolides rifampin . Unable tolerate oral medication . FOR FLUCONAZOLE RANDOMIZATION Serious hypersensitivity reaction fluconazole . Active fungal infection ( cryptococcosis , histoplasmosis , blastomycosis , aspergillosis , Candida esophagitis , thrush , vaginal candidiasis ) . Positive baseline urine cryptococcal culture . Concurrent Medication : Excluded fluconazole randomization : Maintenance therapy deep fungal infection . Chronic therapy ketoconazole fluconazole .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Rifabutin</keyword>
	<keyword>Mycobacterium avium-intracellulare Infection</keyword>
	<keyword>Mycoses</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Azithromycin</keyword>
</DOC>